Drugmaker Cipla said India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the COVID-19 medicine were reported at hospitals. "Cipla's launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India", said Cipla CFO Kedar Upadhye. The drug has been developed by US-based Gilead Sciences.